Three Companies Recall Heparin Products Because of Contaminant
American Health Packaging (AHP, Valley Forge, PA), B. Braun Medical Inc. (Irvine, CA), and Covidien (Mansfield, MA), have all announced voluntary recalls of heparin products after being notified by their supplier, Scientific Protein Laboratories LLC (SPL, Waunakee, WI), of a nationwide recall of heparin sodium USP active pharmaceutical ingredient (API) because of a heparin-like contaminant.
American Health Packaging (AHP, Valley Forge, PA), B. Braun Medical Inc. (Irvine, CA), and Covidien (Mansfield, MA), have all announced voluntary recalls of heparin products after being notified by their supplier, Scientific Protein Laboratories LLC (SPL, Waunakee, WI), of a nationwide recall of heparin sodium USP active pharmaceutical ingredient (API) because of a heparin-like contaminant.
On March 20, American Health Packaging announced a recall of 1,421 units (25 vials per unit) of 10,000 USP units/mL heparin sodium injection 1 mL vials. The vials were manufactured by Baxter Healthcare (Deerfield, IL) and then placed by AHP into individually labeled bags for use in pharmacy automation equipment. The AHP packages where sold to five hospitals in Georgia and California.
On March 21, B. Braun Medical recalled 23 finished product lots, manufactured by B Braun and distributed in the US and Canada.
On March 28, Covidien recalled 32 lots of prefilled heparin lock flush syringes that were manufactured and distributed in the US.
All three companies have recalled their products as a precautionary measure. None of the companies have received adverse event reports related to their products.
The Food and Drug Administration has received reports of serious injuries and deaths in patients who have been administered heparin injectable products made by Baxter from API supplied by SPL that contained a heparin-like contaminant. Typical symptoms include anaphylactic-like reactions such as low blood pressure, shortness of breath, nausea, vomiting, diarrhea, and abdominal pain.
FDA information on heparin recalls
For more information on the heparin situation, see BioPharm International’s previous news coverage:
Heparin Contaminant Identified by FDAFDA Issues Border Alert for All Heparin ProductsGerman Ministry of Health Recalls Heparin ProductsFDA Finds "Heparin-like" Contaminant in Heparin APIBaxter Expands Heparin Recall, FDA Issues 483 to China FacilityLetters Sent to Baxter and FDA Request Answers on Heparin Situation
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
